Shares of non-opioid painkiller maker Latigo rose modestly after its upsized IPO, signaling investor interest in the biotech's pain management solutions.
BlossomHill's $150 million IPO, backed by Janus Henderson, underscored biotech demand and could lift Janus Henderson's stock on the back of a…
Latigo's $345.6 million IPO highlights Wall Street's bet on non-opioid pain therapies, marking a significant entry for the biotech firm into public…
Braveheart Biotech's $382.5 million upsized IPO underscores robust demand for biotech offerings and may boost sector ETFs like IBB.
Attovia Therapeutics stock jumps 24% in trading debut after $289 million biotech IPO, reflecting strong demand for new healthcare listings.
Fresenius raised its earnings guidance, citing accelerating growth in its hospital and drug units, reinforcing a bullish case for the healthcare stock.
India's Manipal Health raised $960 million in its IPO, the largest healthcare listing in Mumbai this year, but shares are set for…
Federal spending cuts set to separate hospital winners from losers, with large chains like HCA Healthcare set to thrive while smaller providers…
Latigo files for $288M US IPO to advance its non-opioid painkiller pipeline, capitalizing on strong investor interest in safer alternatives to addictive…
Sleep-apnea biotech Apnimed's stock jumped 38% in its NYSE debut following an upsized US IPO that exceeded initial targets, underscoring strong investor…
AbbVie beat Q2 earnings estimates fueled by Botox demand revival, sending shares higher.
A16z-backed Braveheart seeks $318.8 million in a US IPO, signaling continued vigor in the venture-backed biotech market.